201 related articles for article (PubMed ID: 10451864)
1. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity.
Pons F; Alvarez L; Peris P; Guañabens N; Vidal-Sicart S; Monegal A; Pavía J; Ballesta AM; Muños-Gómez J; Herranz R
Nucl Med Commun; 1999 Jun; 20(6):525-8. PubMed ID: 10451864
[TBL] [Abstract][Full Text] [Related]
2. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone.
Bonnin MR; Moragues C; Nolla JM; Lirón FJ; Roig-Escofet D; Navarro MA
Clin Chem Lab Med; 1998 Jan; 36(1):53-5. PubMed ID: 9594087
[TBL] [Abstract][Full Text] [Related]
6. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
7. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers of bone turnover in Paget's disease of bone.
Delmas PD
J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216
[TBL] [Abstract][Full Text] [Related]
9. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
10. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
11. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
[TBL] [Abstract][Full Text] [Related]
12. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
[TBL] [Abstract][Full Text] [Related]
13. Skeletal distribution and biochemical parameters of Paget's disease.
Meunier PJ; Salson C; Mathieu L; Chapuy MC; Delmas P; Alexandre C; Charhon S
Clin Orthop Relat Res; 1987 Apr; (217):37-44. PubMed ID: 3103964
[TBL] [Abstract][Full Text] [Related]
14. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N
Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
17. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
18. The diphosphonate space: a useful quantitative index of disease activity in patients undergoing hydroxy methylene diphosphonate (HMDP) bone imaging for Paget's disease [corrected].
Evans A; Perkins A; Wastie M; Stone M; Hosking D
Eur J Nucl Med; 1991; 18(9):757-9. PubMed ID: 1809266
[TBL] [Abstract][Full Text] [Related]
19. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers of bone turnover in Paget's disease.
Russell RG; Beard DJ; Cameron EC; Douglas DL; Forrest AR; Guilland-Cumming D; Paterson AD; Poser J; Preston CJ; Milford-Ward A; Woodhead S; Kanis JA
Metab Bone Dis Relat Res; 1981; 3(4-5):255-62. PubMed ID: 6220191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]